Dupilumab in the treatment of asthma

Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis

(2018) Zuzhen Ou et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma

(2018) Steven F. Weinstein et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

New Biologics for Asthma

(2018) Jeffrey M. Drazen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

(2018) Klaus F. Rabe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

(2018) Mario Castro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials

(2018) Reynold A Panettieri et al.   Lancet Respiratory Medicine

Dupilumab Improves Sense of Smell and Reduces Anosmia Among Patients with Nasal Polyposis and Chronic Sinusitis: Results from a Phase 2a Trial

(2017) Robert M. Naclerio et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

(2017) Andrew Blauvelt et al.   LANCET

Biologic therapy in the management of asthma

(2016) Jennifer L. McCracken et al.   Current Opinion in Allergy and Clinical Immunology

Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis

(2016) Claus Bachert et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

(2016) Sally Wenzel et al.   LANCET

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

(2016) Eric L. Simpson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

(2016) Nicola A Hanania et al.   Lancet Respiratory Medicine

Targeting key proximal drivers of type 2 inflammation in disease

(2015) Namita A. Gandhi et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting eosinophils in allergy, inflammation and beyond

(2013) Patricia C. Fulkerson et al.   NATURE REVIEWS DRUG DISCOVERY

Inhibiting Interleukin-4 and Interleukin-13 in Difficult-to-Control Asthma

(2013) Michael E. Wechsler   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab in Persistent Asthma with Elevated Eosinophil Levels

(2013) Sally Wenzel et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti–IL-4 receptor α antagonist

(2012) Rebecca E. Slager et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Asthma outcomes: Pulmonary physiology

(2012) Robert S. Tepper et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Psychometric validity of the 22-item Sinonasal Outcome Test

(2009) C. Hopkins et al.   CLINICAL OTOLARYNGOLOGY

Interleukin-4 and Interleukin-13 Enhance Human Bronchial Smooth Muscle Cell Proliferation

(2008) Ynuk Bossé et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY